Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer

Tetsuyuki Hirahata, Reeshan ul Quraish, Afraz ul Quraish, Shahian ul Quraish, Munazzah Naz and Mohammad Abdul Razzaq

Hirahata Gene Therapy Laboratory, HIC Clinic, Tokyo, Japan.

ABSTRACT: Cancer is a leading cause of morbidity and mortality worldwide. Over the past decades, the concept of precision cancer medicine has emerged as a novel approach in the field of oncology that aims to tailor the most effective treatment options to each individual cancer patient based on the genetic profile of the tumor of each individual patient. Recently, tissue biopsy has become an essential part of cancer care and is widely used to characterize the tumor. However, tissue biopsy techniques face different challenges due to their invasiveness, cost, time, and adversity in potential sampling due to tissue heterogeneity. To overcome these issues, a non-invasive approach has developed, which is known as liquid biopsy. It is a simple, fast, and worthwhile technique based on the analysis of circulating tumor DNA (which is a fraction of cfDNA), circulating tumor cells (CTCs), and other tumor-derived material in blood plasma. This review provides an overview of the concept of liquid biopsy and briefly discusses the role of ctDNA and CTC analysis as tools for early diagnosis and prognosis of cancer. In this review, we also speculate on the advantages of liquid biopsy as opposed to tissue biopsy and postulate that liquid biopsy may be a comprehensive approach to overcome the current limitations associated with costly, invasive, and time-consuming tissue biopsy.

KEYWORDS: Cancer, liquid biopsy, tissue biopsy, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs)

Introduction

Cancer is a term for a distinctive disease characterized by uncontrolled abnormal cell proliferation, which can invade nearby tissues and metastasize to distant organs through the blood and lymph systems. Metastatic spread of cancer to distant sites remains the main cause of death for cancer patients in 90% of cases. For cancer treatment, conventional cancer therapies practiced in the clinic include systemic chemotherapy (including hormonal therapy and molecular targeted drugs), surgery and radiotherapy, and the choice of therapy depends on the type and stage of the tumor, as well as the general state and age of the patient. These conventional therapies are generally effective against early-stage localized tumors, whereas their effectiveness is not the same against a later stage of cancer and there are chances of frequent relapse.

Drug resistance appears to be a serious problem in treatment of cancer; currently, 90% of chemotherapy failures occur during the invasion and metastasis of cancers related to drug resistance. In chemotherapy, by following the administration of a certain drug, a large number of patient tumor cells become resistant to the drug.

Although many types of cancer are initially susceptible to chemotherapy, over time they can develop resistance to traditional therapies through different mechanisms, such as drug inactivation, epigenetics, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and epithelial-mesenchymal transition (EMT). These mechanisms promote direct or indirect drug resistance in human cancer cells, acting independently or in combination and through various signal transduction pathways.

One study showed that mutations in self-controlling negative feedback in signal transmission can produce resistance for drugs targeting such signaling pathways. Furthermore, tumor cells may also lack antigenic mutations, or some key molecules of the immune system are perhaps absent, such as HLA, and these cells can become unsusceptible to immuno-therapy drugs.

In addition, various agents used in conventional therapies are harmful both to normal cells and cancer cells, which can lead to prominent side effects. These conventional cytotoxic treatments also lack specificity for tumor cells, making them ineffective in providing lifelong protection against cancer.

Therefore, there was an urgent need for new therapeutic strategies that allow more effective monitoring of cancer status, thereby improving the efficacy of treatment by specifically eliminating cancer cells and sparing normal cells from toxicity to develop long-lasting protection.

As a result of recent advancements in medical and pharmacogenetic research, the field of oncology has introduced a profound innovative approach that overcomes the old one-size-fits-all strategy; this new paradigm is known as precision medicine, which is designed to customize therapies for patients in relation to the personalized molecular profile of the tumor. So far, the path of survival of cancer patients is tissue dependent, known as tissue biopsy, which has several advantages over conventional cancer treatments.

Tissue Biopsy

Tissue biopsy involves the examination of tumor tissue by obtaining tissue through a fine needle or open surgery, these...
tissue samples are genetically analyzed to define the type of tumor and then the best personalized treatment regimen is designed.

**Drawbacks of tissue biopsy**

Despite the informative nature of tissue biopsy, it is painful, invasive, costly, time consuming, and, most importantly, sometimes inappropriate to capture tumor heterogeneity. Apart from other issues related to tissue biopsy, intratumoral heterogeneity is always a potential issue in the precision of this procedure, which induces significant challenges in selecting an effective treatment strategy based only on tissue biopsy.

Tissue biopsies typically obtain a sample of only a part of the tumor and therefore encompass only a fraction of tumor heterogeneity, as serial tumor sampling is not clinically practical with invasive tissue biopsy; therefore, complete information on the levels of genetic and epigenetic variability of a patient’s cancer is not achieved.

Invasive tissue biopsy has also been studied to be impossible after surgical resection and if there is no detectable metastatic mass.

Moreover, unsatisfactory detection of early-stage tumor or residual lesions, also causing limitations of this therapy. Therefore, a worthwhile and noninvasive approach has been developed that could proficiently capture the genomic content of tumors in fluids and detect tumor heterogeneity in the course of cancer treatments; this approach is known as liquid biopsy that provides noninvasive multifunctional biomarkers for early diagnosis, accurate prognosis, selection of therapeutic targets, monitoring of metastases, as well as monitoring response and resistance to treatment.

**Liquid Biopsy**

The term liquid biopsy is basically introduced for the analysis of CTCs but is now also associated with ctDNA and other biomarkers such as miRNAs. In addition to blood, several body fluids such as blood, plasma, serum, saliva, urine, and gastric juice could be used to perform liquid biopsy for non-invasive clinical evaluation.

The clinical use of liquid biopsy has increased significantly since 2004, when Guardant Health released the first commercially available liquid biopsy test. Liquid biopsy (restricted to ctDNA analysis) was officially adopted as a diagnostic tool in the main reference center laboratories during the course of 2016.

Currently, there are several commercially available assays that are FDA approved; some are considered proficient in treatment capability by insurance companies. For example, in 2016, the FDA approved cobas EGFR Mutation Test v2 to determine the eligibility of patients with non-small cell lung cancer to receive certain EGFR tyrosine kinase inhibitors.

**Liquid biopsy: A comprehensive approach to overcome the current limitations associated with tissue biopsy**

Liquid biopsy represents a contemporary diagnostic and prognostic tool in precision oncology that has received considerable recognition over the past years to overcome the current limitations associated with tissue biopsies.

For example, cancer is often found in organs or tissues of the body that are difficult to access, such as in lung cancer, tissue-resident biomarker measurements are clinically often not possible due to significant clinical risk, such as bleeding, injury, or infection as a consequence of an invasive tissue biopsy; therefore, liquid biopsy has the advantages of being a noninvasive and sustainable technique to solve this problem.

In the perspective of tumor heterogeneity, serial liquid biopsy can be a better representative of the entire population of tumor cells than a tissue biopsy sample, can monitor tumor heterogeneity longitudinally, and allows successive monitoring of the tumor genetic profile.

Furthermore, unlike tissue biopsies, liquid biopsy enables the detection of tumor at an early stage; early detection of tumor not only prevents cancer mortality, but also reduces morbidity and costs.

**Approaches to liquid biopsy analysis**

Liquid biopsy comprises the noninvasive analysis of ctDNA and CTCs. In addition to ctDNA and CTC biomarkers, other blood components recently discovered as sources of blood-based biomarkers, such as exosomes or platelets, but in this review we will focus on circulating tumor DNA (ctDNA) and circulating tumor cell (CTC).

**Cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA).** Circulating cell-free DNA (cfDNA) and circulating tumor DNA are significant non-invasive blood biomarkers used to assess tumor diagnosis and prognosis.

**Discovery of cfDNA and ctDNA.** Mandel and Metais discovered the presence of cfDNA in the blood of healthy individuals in 1948. Decades later, many researchers have extended Mandel and Metais’ work to the identification of tumor-derived cfDNA (also known as circulating tumor DNA-ctDNA) in the blood of cancer patients.

According to previous reports, ctDNA possesses many cancer-associated molecular characteristics, such as single nucleotide mutations, methylation changes, cancer-derived viral sequences, rearrangements, amplifications, MSI and LOH, therefore, it was considered derived from tumor tissue.

**Presence of cfDNA and ctDNA in the body.** It is mainly found in the bloodstream; now it can be derived from cerebrospinal fluid, saliva, and can be excreted through urine with extremely low content. Recently, ctDNA has been shown to be present in the CSF of patients with brain tumors, and a high percentage...
of tumor DNA has also been observed in the saliva of patients with oral cavity cancer.44-46

**Release of cfDNA and ctDNA in the blood stream.** Two mechanisms for the release of DNA into the blood circulation have been postulated. The first is the passive release of DNA through cell death either by apoptosis or necrosis.47

Another mechanism of ctDNA release is active secretion by viable tumor cells,47,48 secretion occurs by the release of extracellular vesicles, such as exosomes and prostasomes, which contain DNA pieces of around 150 to 250 bp.49

**Elevated level of cfDNA and ctDNA in cancer patient.** In general, cancer patients have an elevated level of circulating free DNA (Figure 1) than healthy individuals.50-52

In 1977, scientists made the dynamic observation of abnormally high levels of cfDNA in plasma and serum from cancer patients compared to healthy individuals, and this fraction of cfDNA originated from cancer patients was assumed to represent mainly circulating tumor DNA (ctDNA).51,53

**Concentration and size of cfDNA and ctDNA fragments in cancer patient.** Initial studies showed that the concentration of cfDNA in cancer patients increased significantly compared to a healthy individual that ranges from 0 to 1000 ng/mL of blood, with an average of 180 ng/mL. In contrast, cfDNA in healthy individuals ranges from 0 to 100 ng/mL of blood, with an average of 30 ng/mL.49,51

Another amazing feature of ctDNA is the wide variability in the fragment size. This variability can be attributed to the variety of mechanisms that underlie dead cancer cells. In healthy individuals, cfDNA is released predominantly through apoptosis with small and uniform fragments of around 185 to 200 bp.54,55

In cancer patients, due to incomplete and random digestion of genomic DNA by the nuclease enzyme, necrosis creates a spectrum of DNA fragments of various sizes, interestingly, shorter fragments of ctDNA have been reported in some tumor types (eg, hepatocellular carcinomas) as well as large fragments of ctDNA of thousands of base pairs.50,54-58

These studies show that the concentration and length of the ctDNA fragment can be used for the prediction, early diagnosis, and prognosis of cancer.59

**Clinical application of cfDNA and ctDNA.** Conventionally, protein biomarkers are used in cancer diagnosis and in the evaluation of therapeutic responses, such as carcinoembryonic antigen (CEA), prostate specific antigen (PSA), cancer antigen (CA) 19-9 and CA-125, but the specificity and reliability of these protein biomarkers are not satisfactory.60,61 Recently, ctDNA has been the most commonly used type of blood-based biomarker candidate in clinical practice. Specifically, ctDNA analysis has been used primarily to monitor response to therapy, detect minimal residual disease throughout treatment, and evaluate the development of resistance to therapy.62-67

Of many potential clinical benefits of ctDNA, early detection in cancer diagnosis can be an important approach to reduce cancer mortality,68 and several studies have also reported the detection of genetic alterations in patients with early stage cancer that support the role of ctDNA in early detection of cancer.69-73

Many studies have also shown that ctDNA can be a powerful prognostic factor. For example, in the case of triple-negative breast cancer patients, the detection of ctDNA during or after neoadjuvant chemotherapy, and prior to surgery, has been shown to have a strong prognostic value.74

Another study in pancreatic cancer showed that higher levels of total percentage of ctDNA were an independent prognostic factor for overall survival.75

In addition, several studies have compared cfDNA levels in cancer patients with healthy individuals and those with benign conditions, showing promising diagnostic and prognostic applications of ctDNA. For example, plasma cfDNA levels have been reported to be elevated in metastatic RCC relative to
localized disease, and in the case of bladder cancer, urine cfDNA levels were found to be significantly elevated compared to controls. Plasma levels of cfDNA have also been reported to be elevated compared to benign prostatic hyperplasia (BPH). Similar to some studies in melanoma, breast, ovarian, and colon cancers, elevated levels of cfDNA can serve as a noninvasive predictor and prognostic biomarker of cancer.

Furthermore, ctDNA can potentially help detect cancer recurrence much earlier than current conventional procedures. For example, a study of breast cancer patients shows that ctDNA monitoring is a precise method for the early detection of asymptomatic metastatic recurrence in patients diagnosed with primary breast cancer. According to another study, patient-specific ctDNA analysis can be a more sensitive and specific approach to detecting recurrence in breast cancer compared to standard clinical and radiological surveillance, and provides evidence that ctDNA can be detected in most patients with breast cancer several months before clinical relapse. Postoperative detection of ctDNA has also been shown to remain strongly predictive of recurrence among patients with both lower risk (pathological complete response—pCR) and higher risk (pathologic node-positive—pN+) disease.

Another potential role for analyzing ctDNA levels is to assess treatment response or resistance; which involves quantitative measurement of the level of ctDNA over time in response to cancer treatments. Monitoring of treatment response is essential to avoid continuing ineffective therapies, to prevent unnecessary side effects, and to determine the benefit of new therapies. Treatment response is generally assessed using serial imaging, but radiographic measurements often do not detect changes in tumor burden. Dawson et al. reported that circulating tumor DNA levels showed a greater correlation with changes in tumor burden, and provided the earliest assessment of treatment response in 10 of 19 women (53%) measuring tumor burden with high sensitivity and specificity.

Circulating tumor cells (CTCs). CTCs discovered by Ashworth in 1869 during an autopsy of a patient with metastatic cancer. These intact tumor cells are released into the bloodstream from primary and secondary tumor sites, and their migration to the circulatory system results in the development of distant metastases. CTCs are observed in different sites or unsuccessful sampling; CTCs would be a perceptive approach over tissue biopsy.

Numbers of CTCs present in the bloodstream. They are rarely found in clinically healthy people or in people with non-malignant tumors. A study showed that patients with metastases have 1 to 10 CTCs per mL of blood, with even lower numbers in early-stage diseases.

Basically, the low number of CTCs isolated from a patient, especially at the beginning of the disease, is the main challenge in using CTCs for diagnostic purposes. However, with the development of technologies capable of dealing with minimal cell numbers, such as microfluidics and NGS, the CTC analysis is now in a position to address highly relevant questions.

Isolation and detection of CTCs. CTCs are observed in different types of cancer, such as melanoma, breast, ovarian, prostate, lung, colorectal, pancreatic, head, neck, and bladder cancer. They are present in various biological fluids of cancer patients, such as peripheral blood (Figure 2), urine, pleural effusion, ascites, and cerebrospinal fluid.

Techniques for the detection and isolation of these biomarkers were first described in 1960 and gradually improved over the next 40 years. The CellSearch system is reported as a validated method for CTC detection that has been approved by the US Food and Drug Administration. The CellSearch system, designed for the CTC enumeration in 7.5 mL of blood, was first introduced in 2004 where the analytical accuracy, reproducibility, and linearity of the system were demonstrated.

Clinical application of CTCs. Analysis of CTCs provides information on cellular components, including DNA, RNA, and protein, and can be used as an independent prognostic factor for tumors such as prostate cancer, breast cancer, and colon cancer.

CTC analysis also has the potential to be used as a biomarker for the screening and early detection of cancer. Early detection and characterization of CTCs is an important tool for monitoring and preventing the development of overt metastatic disease.

In patients with metastatic breast cancer, the detection of CTCs has been reported to have a great prognostic value. Another role of circulating tumor cell (CTC) analysis has been reported to monitor response to therapy in patients with advanced non-small cell lung cancer (NSCLC). Changes in CTCs number during treatment have been proposed as a predictive biomarker of response to both chemotherapy and targeted therapies.

CTCs have also been reported to replace tissue biopsies to predict tumor recurrence and in cases of inaccessible neoplastic sites or unsuccessful sampling; CTCs would be a perceptible approach over tissue biopsy.
Conclusion
In summary, liquid biopsy is a significant innovation in the field of precision medicine and has made a competent potential in the treatment of cancer; this revolutionary non-invasive technique consists of the detection and isolation of circulating tumor DNA, circulating tumor cells, and exosomes, as a source of genomic and proteomic information in cancer patients. Analysis of these biomarkers offers a valuable range of information that allows non-invasive diagnosis, prognosis, and treatment of cancer.

Both ctDNA and CTCs are interesting complementary biomarkers of liquid biopsy that can be used in parallel in various aspects of cancer management. Analysis of each biomarker has its own advantages and disadvantages; specifically, ctDNA analysis is an attractive approach because it is simple to isolate and analyze ctDNA, but it is limited to the analysis of DNA-related abnormalities; in contrast, CTC analysis provides profiling of the entire cell; however, it is difficult to isolate a population of rare cells and is not easily adopted in most laboratories. Thus, its clinical applicability will require further research and verification.

Clearly, liquid biopsy opens up a new possibility of non-invasive, safe, and easily repeatable practice in cancer treatment. Despite the advantages of liquid biopsy, more studies are required to address the challenges and limitations of this technique, which restricted its implementation in clinical practice.

However, the multifaceted advantages of liquid biopsy demonstrate its application as a promising prognosis and diagnostic tool in precision oncology, and it may be a comprehensive approach to overcome the current limitations associated with invasive tissue biopsy and can identify multiple tumor genes present in the bloodstream at multiple time points.

Authors Contributions
R.Q. conceptualized, researched and wrote this manuscript. All authors have read and agreed to the published version of the final manuscript.

Ethics Approval and Consent to Participate
This manuscript does not involve the use of animal or human data or tissue, so ethical approval is not applicable in this section.

ORCID iDs
Tetsuyuki Hirahata https://orcid.org/0000-0003-1260-754X
Reeshan ul Quraish https://orcid.org/0000-0002-3609-7583

REFERENCES
1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719-724.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
3. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-1564.
4. Damyanov CA, Maslev IK, Pavlov VS, Avramov L. Conventional treatment of cancer realities and problems. Annu Complement Altern Med. 2018;1:1002.
5. Glazer M, Panje C, Siren C, Cibor A, Putura P. Decision making criteria in oncology. Oncolgy. 2020;98:370-378.
6. Chakraborty S, Rahman T. The difficulties in cancer treatment. Easamemedica. 2012;6:ed16.
7. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy: use of methyl-bis (beta-chloroethyl) amine hydrochloride and tri beta-chloroethyl amine hydrochloride for
